EP3468552A4 - SELECTIVE LIGANDS OF THE ANDROGEN RECEPTOR DEGREE (SARD) AND METHOD FOR USE THEREOF - Google Patents

SELECTIVE LIGANDS OF THE ANDROGEN RECEPTOR DEGREE (SARD) AND METHOD FOR USE THEREOF Download PDF

Info

Publication number
EP3468552A4
EP3468552A4 EP17811167.0A EP17811167A EP3468552A4 EP 3468552 A4 EP3468552 A4 EP 3468552A4 EP 17811167 A EP17811167 A EP 17811167A EP 3468552 A4 EP3468552 A4 EP 3468552A4
Authority
EP
European Patent Office
Prior art keywords
sard
androgen receptor
selective ligands
degree
receptor degree
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17811167.0A
Other languages
German (de)
French (fr)
Other versions
EP3468552A1 (en
Inventor
Ramesh Narayanan
Duane Miller
Thamarai PONNUSAMY
Dong-Jin Hwang
Yali He
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of EP3468552A1 publication Critical patent/EP3468552A1/en
Publication of EP3468552A4 publication Critical patent/EP3468552A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Electrochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP17811167.0A 2016-06-10 2017-06-12 SELECTIVE LIGANDS OF THE ANDROGEN RECEPTOR DEGREE (SARD) AND METHOD FOR USE THEREOF Pending EP3468552A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662348474P 2016-06-10 2016-06-10
US201762455397P 2017-02-06 2017-02-06
US201762482036P 2017-04-05 2017-04-05
PCT/US2017/037063 WO2017214634A1 (en) 2016-06-10 2017-06-12 Selective androgen receptor degrader (sard) ligands and methods of use thereof

Publications (2)

Publication Number Publication Date
EP3468552A1 EP3468552A1 (en) 2019-04-17
EP3468552A4 true EP3468552A4 (en) 2020-07-08

Family

ID=60578186

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17811167.0A Pending EP3468552A4 (en) 2016-06-10 2017-06-12 SELECTIVE LIGANDS OF THE ANDROGEN RECEPTOR DEGREE (SARD) AND METHOD FOR USE THEREOF

Country Status (10)

Country Link
US (1) US10314797B2 (en)
EP (1) EP3468552A4 (en)
JP (2) JP6956747B2 (en)
KR (2) KR20230005416A (en)
CN (1) CN109310664A (en)
AU (2) AU2017278314B2 (en)
CA (1) CA3024615A1 (en)
IL (1) IL263613B (en)
MX (2) MX393924B (en)
WO (1) WO2017214634A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US10806720B2 (en) * 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
KR20220071293A (en) 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 Estrogen receptor modulators
US10806719B2 (en) 2016-06-10 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
EP3793541A4 (en) * 2018-05-16 2022-03-02 GTx, Inc. SELECTIVE ANDROGEN RECEPTOR DEGRADING COMPOUND (SARD) LIGANDS AND METHODS OF USE THEREOF
WO2020051260A1 (en) * 2018-09-05 2020-03-12 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
WO2020051344A1 (en) * 2018-09-05 2020-03-12 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
EP3976577A4 (en) * 2019-05-29 2023-06-28 University of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
KR20220044528A (en) 2019-08-06 2022-04-08 리커리엄 아이피 홀딩스, 엘엘씨 Estrogen receptor modulators to treat mutants
KR20220087482A (en) * 2019-10-22 2022-06-24 아비나스 오퍼레이션스, 인코포레이티드 How to treat prostate cancer
EP4110327A4 (en) * 2020-02-25 2024-03-13 University of Tennessee Research Foundation SELECTIVE ANDROGEN RECEPTOR DEGRADING COMPOUND (SARD) LIGANDS AND METHODS OF USE
KR20220146532A (en) * 2020-02-25 2022-11-01 유니버시티 오브 테네시 리서치 파운데이션 Selective androgen receptor shared antagonists (SARCAs) and methods of use thereof
CN111348611B (en) * 2020-03-10 2023-05-09 西南大学 A neuron-like optical pulse output system based on a silicon-based microcavity
IL296743A (en) * 2020-04-02 2022-11-01 Univ Tennessee Res Found Pyrazolylpropanamide compounds and their use in the treatment of prostate cancer
CN111796099B (en) * 2020-06-03 2022-02-11 温州医科大学 Application and kit for preparing diagnostic reagent for distinguishing hormone sensitivity and castration resistance of prostate cancer, and method and device
WO2023011596A1 (en) * 2021-08-05 2023-02-09 中国药科大学 Amide compound and use thereof
CN116354933B (en) * 2021-12-27 2025-06-20 青岛普泰科生物医药科技有限公司 Heterocyclic compounds as androgen receptor modulators and their use
EP4219454B1 (en) 2022-01-28 2025-11-19 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Highly efficient process for the preparation of 4-fluoro-1h-pyrazole or salts thereof
WO2024010817A2 (en) * 2022-07-07 2024-01-11 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) o-linked ligands and methods of use thereof
WO2024010815A2 (en) * 2022-07-07 2024-01-11 University Of Tennessee Research Foundation Non-steroidal dual androgen and glucocorticoid receptor antagonists
WO2025067483A1 (en) * 2023-09-28 2025-04-03 中国药科大学 Amide compounds

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253503A2 (en) * 1986-07-18 1988-01-20 Imperial Chemical Industries Plc Substituted anilides having antiandrogenic properties
US6472415B1 (en) * 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
WO2003074473A2 (en) * 2002-02-28 2003-09-12 University Of Tennessee Research Foundation Irreversible selective androgen receptor modulators and methods of use thereof
CN1597662A (en) * 2003-09-16 2005-03-23 中国科学院上海药物研究所 A kind of aromatic acid amide compound its preparation method and use
US7186854B2 (en) * 2002-10-02 2007-03-06 Synthon Ip Inc. Process for making bicalutamide and intermediates thereof
US20070265290A1 (en) * 2002-10-15 2007-11-15 Dalton James T Heterocyclic selective androgen receptor modulators and methods of use thereof
WO2008044033A1 (en) * 2006-10-11 2008-04-17 Astrazeneca Ab Amide derivatives
WO2008137038A1 (en) * 2007-05-03 2008-11-13 Yale University Locally active 'soft' antiandrogens
US20100331418A1 (en) * 2009-06-29 2010-12-30 Koh John Tze-Tzun Pan-Antagonists For The Androgen Receptor And Androgen Receptor Mutants Associated With Anti-Androgen Withdrawal
WO2013064681A1 (en) * 2011-11-04 2013-05-10 Galderma Research & Development N-(pyrid-4-yl)amides and n-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use
WO2016172358A1 (en) * 2015-04-21 2016-10-27 Gtx, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
WO2016172330A1 (en) * 2015-04-21 2016-10-27 Gtx, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100516A (en) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
JP3277342B2 (en) 1992-09-02 2002-04-22 武田薬品工業株式会社 Manufacturing method of sustained release microcapsules
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
GB0003790D0 (en) 2000-02-18 2000-04-05 Astrazeneca Uk Ltd Medical device
AU2002367424A1 (en) * 2001-12-28 2003-07-24 Takeda Chemical Industries, Ltd. Androgen receptor antagonists
JP2005529952A (en) * 2002-06-17 2005-10-06 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション N-bridge selective androgen receptor modulator and method of using the same
CA2502209A1 (en) * 2002-10-15 2004-04-29 University Of Tennessee Research Foundation Methylene-bridged selective androgen receptor modulators and methods of use thereof
JPWO2009028543A1 (en) 2007-08-30 2010-12-02 武田薬品工業株式会社 Substituted pyrazole derivatives
ATE552111T1 (en) * 2008-09-02 2012-04-15 Agfa Graphics Nv HEAT SENSITIVE, POSITIVE WORKING LITHOGRAPHY PRINTING FORM PRECURSOR
LT2872482T (en) * 2012-07-13 2020-12-28 Oncternal Therapeutics, Inc. A method of treating breast cancers with selective androgen receptor modulator (sarm)
US10093613B2 (en) * 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US9834507B2 (en) * 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253503A2 (en) * 1986-07-18 1988-01-20 Imperial Chemical Industries Plc Substituted anilides having antiandrogenic properties
US6472415B1 (en) * 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
WO2003074473A2 (en) * 2002-02-28 2003-09-12 University Of Tennessee Research Foundation Irreversible selective androgen receptor modulators and methods of use thereof
US7186854B2 (en) * 2002-10-02 2007-03-06 Synthon Ip Inc. Process for making bicalutamide and intermediates thereof
US20070265290A1 (en) * 2002-10-15 2007-11-15 Dalton James T Heterocyclic selective androgen receptor modulators and methods of use thereof
CN1597662A (en) * 2003-09-16 2005-03-23 中国科学院上海药物研究所 A kind of aromatic acid amide compound its preparation method and use
WO2008044033A1 (en) * 2006-10-11 2008-04-17 Astrazeneca Ab Amide derivatives
WO2008137038A1 (en) * 2007-05-03 2008-11-13 Yale University Locally active 'soft' antiandrogens
US20100331418A1 (en) * 2009-06-29 2010-12-30 Koh John Tze-Tzun Pan-Antagonists For The Androgen Receptor And Androgen Receptor Mutants Associated With Anti-Androgen Withdrawal
WO2013064681A1 (en) * 2011-11-04 2013-05-10 Galderma Research & Development N-(pyrid-4-yl)amides and n-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use
WO2016172358A1 (en) * 2015-04-21 2016-10-27 Gtx, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
WO2016172330A1 (en) * 2015-04-21 2016-10-27 Gtx, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COLIN THOMAS ET AL: "New access to fluorinated ketoglycolic acid derivatives from trifluoropyruvamides", TETRAHEDRON LETTERS, vol. 45, no. 29, 2004, pages 5611 - 5613, XP085009208, ISSN: 0040-4039, DOI: 10.1016/J.TETLET.2004.05.128 *
DATABASE GNPD [online] MINTEL; 5 December 2007 (2007-12-05), ANONYMOUS: "Compound Summary for CID 20221988-C12H13N3O", XP055457667, retrieved from www.gnpd.com Database accession no. CID 20221988 *
MICHAEL L MOHLER ET AL: "Androgen receptor antagonists: a patent review (2008 - 2011)", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 22, no. 5, 1 May 2012 (2012-05-01), pages 541 - 565, XP055111543, ISSN: 1354-3776, DOI: 10.1517/13543776.2012.682571 *
SCHRAGL KATHARINA M ET AL: "Novel pathway for the synthesis of arylpropionamide-derived selective androgen receptor modulator (SARM) metabolites of andarine and ostarine", TETRAHEDRON LETTERS, ELSEVIER LTD, AMSTERDAM, NL, vol. 54, no. 18, 27 February 2013 (2013-02-27), pages 2239 - 2242, XP028527032, ISSN: 0040-4039, DOI: 10.1016/J.TETLET.2013.02.065 *
SELIGSON A L ET AL: "Development of fluridil, a topical suppressor of the androgen receptor in androgenetic alopecia", vol. 59, no. 3, 1 July 2003 (2003-07-01), pages 292 - 306, XP002683908, ISSN: 0272-4391, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/doi/10.1002/ddr.10166/abstract> [retrieved on 20030715], DOI: 10.1002/DDR.10166 *

Also Published As

Publication number Publication date
JP7382987B2 (en) 2023-11-17
IL263613A (en) 2019-01-31
US20170368003A1 (en) 2017-12-28
KR20190016513A (en) 2019-02-18
EP3468552A1 (en) 2019-04-17
BR112018075347A2 (en) 2019-03-19
AU2022235644A1 (en) 2022-10-20
KR102481319B1 (en) 2022-12-26
IL263613B (en) 2021-04-29
KR20230005416A (en) 2023-01-09
CA3024615A1 (en) 2017-12-14
JP2021138780A (en) 2021-09-16
RU2018139930A (en) 2020-07-10
AU2017278314A1 (en) 2018-12-13
AU2022235644B2 (en) 2024-06-13
CN109310664A (en) 2019-02-05
MX2018015179A (en) 2019-10-14
JP6956747B2 (en) 2021-11-02
WO2017214634A1 (en) 2017-12-14
JP2019522644A (en) 2019-08-15
US10314797B2 (en) 2019-06-11
MX393924B (en) 2025-03-24
MX2021003784A (en) 2021-05-27
AU2017278314B2 (en) 2022-06-30
RU2018139930A3 (en) 2020-09-29

Similar Documents

Publication Publication Date Title
EP3468552A4 (en) SELECTIVE LIGANDS OF THE ANDROGEN RECEPTOR DEGREE (SARD) AND METHOD FOR USE THEREOF
EP3548136A4 (en) NEUROMODULATION DEVICE AND METHOD FOR USE
EP3464360C0 (en) ANTI-TIM-3 ANTIBODIES AND METHOD FOR USE THEM
EP3436036A4 (en) BCMA-BINDING MOLECULES AND METHOD FOR USE THEREOF
EP3701245A4 (en) SYSTEM AND METHOD FOR PARTICLE MEASUREMENT
EP4008728C0 (en) CD70-Binding Molecules and Methods for Using Them
EP3310378C0 (en) ANTI-CLL-1 ANTIBODIES AND METHOD OF USE
EP3515478A4 (en) ANTIBODIES FOR SIGLEC-15 AND METHOD FOR USE THEREOF
EP3970680C0 (en) MEDICAL-TECHNOLOGICAL STATION AND METHOD OF USE
EP3245291C0 (en) Novel microdystrophins and associated methods for use
EP3445251A4 (en) BIOPSY DEVICES AND METHOD FOR USE THEREOF
EP3518972A4 (en) ANTIGEN-BINDING MOLECULES AND METHOD FOR USE THEREOF
EP3478723A4 (en) PD-L1-S-SPECIFIC ANTIBODIES AND METHOD FOR USE THEREOF
EP3709691C0 (en) METHOD AND APPARATUS FOR PROFILE DOWNLOAD OF GROUP DEVICES
EP3394598C0 (en) METHOD AND DEVICE FOR MONITORING AND CONTROLLING THE FORMATION OF DEPOSITS
EP3175435C0 (en) SYSTEM AND METHOD FOR CONTROLLING THE RELEASE OF DRONES
EP3551033A4 (en) ENDOSCOPE AND METHOD FOR USE
EP3538128A4 (en) ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHOD FOR USE THEREOF
EP3548440A4 (en) LIQUID TREATMENT SYSTEMS AND METHOD FOR USE THEREOF
EP3558502A4 (en) REVERSE OSMOSMEMBRANE AND METHOD FOR USE
EP3460038A4 (en) REACTION TREATMENT DEVICE AND METHOD FOR CONTROLLING THE REACTION TREATMENT DEVICE
EP3203915C0 (en) ULTRASONIC PROBE PARAMETER LOADERS AND ASSOCIATED APPARATUS AND METHOD
EP3507365A4 (en) METHOD AND COMPOSITIONS FOR PHASE CONTROLLED SEQUENCING
EP3536015A4 (en) METHOD AND DEVICE FOR SETTING SUBBAND-CSI-ASSOCIATED PARAMETERS
EP3451838A4 (en) SPIRAL COOKING DEVICES AND METHOD FOR USE THEREOF

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181224

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/40 20060101ALI20200309BHEP

Ipc: A61K 31/4196 20060101ALI20200309BHEP

Ipc: A61K 31/4164 20060101ALI20200309BHEP

Ipc: A61K 31/415 20060101ALI20200309BHEP

Ipc: A61K 31/325 20060101AFI20200309BHEP

Ipc: A61P 35/00 20060101ALI20200309BHEP

Ipc: C07C 271/02 20060101ALI20200309BHEP

Ipc: A61K 45/06 20060101ALI20200309BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40007707

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20200610

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 17/10 20060101ALI20200604BHEP

Ipc: A61K 31/40 20060101ALI20200604BHEP

Ipc: A61P 17/00 20060101ALI20200604BHEP

Ipc: A61P 5/24 20060101ALI20200604BHEP

Ipc: A61P 17/14 20060101ALI20200604BHEP

Ipc: A61K 31/415 20060101ALI20200604BHEP

Ipc: A61P 15/00 20060101ALI20200604BHEP

Ipc: A61P 25/18 20060101ALI20200604BHEP

Ipc: A61K 31/325 20060101AFI20200604BHEP

Ipc: C07C 271/02 20060101ALI20200604BHEP

Ipc: A61P 17/08 20060101ALI20200604BHEP

Ipc: A61K 45/06 20060101ALI20200604BHEP

Ipc: A61P 13/08 20060101ALI20200604BHEP

Ipc: A61P 35/00 20060101ALI20200604BHEP

Ipc: A61K 31/4164 20060101ALI20200604BHEP

Ipc: A61P 9/00 20060101ALI20200604BHEP

Ipc: A61P 35/04 20060101ALI20200604BHEP

Ipc: A61P 21/00 20060101ALI20200604BHEP

Ipc: A61P 43/00 20060101ALI20200604BHEP

Ipc: A61K 31/4196 20060101ALI20200604BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231023

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40007707

Country of ref document: HK